StockData
Immatics N.V. logo

Immatics N.V. (IMTX) stock

IMTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 1/30
$6.10−0.19 (-3.02%)

Close on Nov 18, 2026Market cap $817.84MP/E –Yield –

Immatics net income

Net income is the profit left for shareholders after every expense, interest and tax.

For fiscal 2023 it was -€94.65M, down 441.7% from the year before. The highest annual figure on record is €27.70M in fiscal 2022.

Annual net income

PeriodPeriod endValueChange
FY2023Dec 31, 2023-€94.65M-441.7%
FY2022Dec 31, 2022€27.70M–
FY2021Dec 31, 2021-€93.34M–
FY2020Dec 31, 2020-€211.28M–
FY2019Dec 31, 2019-€31.57M–
FY2018Dec 31, 2018-€31.44M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2024Sep 30, 2024-€5.31M–
Q2 FY2024Jun 30, 2024-€17.99M–
Q1 FY2024Mar 31, 2024-€2.24M–
Q2 FY2021Jun 30, 2021-€26.53M–
Q2 FY2020Jun 30, 2020-€21.04M–

More Immatics figures

See a number that looks wrong?